Clinical Data Viridian tumbles on positive data for key eye drug prospect BioPharma DiveThe data did not meet investor expectations, and could bring fierce investor debate on commercial feasibility, according to an analyst.Clinical DataOphthalmologyRead full story pharminent March 31, 2026 (Last updated: March 31, 2026) BioPharma Dive The data did not meet investor expectations, and could bring fierce investor debate on commercial feasibility, according to an analyst. Clinical DataOphthalmologyRead full story Post navigation Previous: PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting DiseaseNext: Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
